Xofigo

Xofigo (Radium Ra 223 Dichloride) is a radiopharmaceutical used for targeted therapy in certain cancers. Administered intravenously, it delivers alpha radiation to bone metastases. Suitable for patients seeking advanced cancer treatment options. Short-term storage guidance may apply.

Xofigo is primarily used to treat bone metastases in patients with castration-resistant prostate cancer. It targets areas of high bone turnover, delivering localized radiation. This therapy is often considered when other treatments have not been effective. Patients may ask, 'what is Xofigo used for' to understand its role in cancer care.

Patients may experience fatigue or nausea after receiving Xofigo. Bone pain relief is a reported effect in some cases. The treatment is designed to slow disease progression rather than provide immediate symptom relief. Individual responses can vary widely.

Xofigo should only be handled by healthcare professionals trained in radiopharmaceuticals. Pregnant individuals or those planning pregnancy should avoid exposure. Close contact with others may need to be limited temporarily after treatment. Always disclose medical history to your provider before use.

Limited data exists on drug interactions with Xofigo due to its targeted nature. Concurrent use of other radiopharmaceuticals or chemotherapy may require careful monitoring. Alcohol and certain supplements could affect treatment tolerance. Consult your doctor for personalized guidance.